Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
Cancer|June 14, 2005
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapyAllan Lipton, Kim Leitzel, Suhail M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2016
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive AgentsAllan Lipton, Matthew R Smith, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14Allan Lipton, Judy-Anne W Chapman, Laurence Demers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancerAllan Lipton, Kim Leitzel, Hilary A Chaudri-Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancerAllan Lipton, S M Ali, K Leitzel, et al.
JAMA Oncology|January 27, 2017
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical TrialGabriel N Hortobagyi, Catherine Van Poznak, W Graydon Harker, et al.
Cells|March 6, 2021
Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer TherapeuticsBijesh George, P Mukundan Pillai, Aswathy Mary Paul, et al.
Cancer|September 24, 2010
Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patientsWilliam K Oh, Roberto Vargas, Susanna Jacobus, et al.
Oncotarget|September 9, 2017
Excessive matrix metalloprotease-mediated degradation of interstitial tissue (type I collagen) independently predicts short-term survival in an observational study of postmenopausal women diagnosed with cancerNicholas Willumsen, Cecilie L Bager, Stephanie N Kehlet, et al.
Breast (Edinburgh, Scotland)|January 14, 2024
Diagnostic delays in breast cancer among young women: An emphasis on healthcare providersLuis Costa, Rakesh Kumar, Cynthia Villarreal-Garza, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Cancer|June 14, 2005
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapyAllan Lipton, Kim Leitzel, Suhail M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2016
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive AgentsAllan Lipton, Matthew R Smith, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14Allan Lipton, Judy-Anne W Chapman, Laurence Demers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancerAllan Lipton, Kim Leitzel, Hilary A Chaudri-Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancerAllan Lipton, S M Ali, K Leitzel, et al.
JAMA Oncology|January 27, 2017
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical TrialGabriel N Hortobagyi, Catherine Van Poznak, W Graydon Harker, et al.
Cells|March 6, 2021
Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer TherapeuticsBijesh George, P Mukundan Pillai, Aswathy Mary Paul, et al.
Cancer|September 24, 2010
Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patientsWilliam K Oh, Roberto Vargas, Susanna Jacobus, et al.
Oncotarget|September 9, 2017
Excessive matrix metalloprotease-mediated degradation of interstitial tissue (type I collagen) independently predicts short-term survival in an observational study of postmenopausal women diagnosed with cancerNicholas Willumsen, Cecilie L Bager, Stephanie N Kehlet, et al.
Breast (Edinburgh, Scotland)|January 14, 2024
Diagnostic delays in breast cancer among young women: An emphasis on healthcare providersLuis Costa, Rakesh Kumar, Cynthia Villarreal-Garza, et al.
Pageof 15